​

Coherus Oncology (CHRS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CHRS Stock Forecast

Coherus Oncology (CHRS) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $6.02, with a high of $11.00 and a low of $1.05. This represents a 238.20% increase from the last price of $1.78.

- $3 $6 $9 $12 $15 High: $11 Avg: $6.02 Low: $1.05 Last Closed Price: $1.78

CHRS Stock Rating

Coherus Oncology stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (81.25%), 3 Hold (18.75%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 3 13 Strong Sell Sell Hold Buy Strong Buy

CHRS Price Target Upside V Benchmarks

TypeNameUpside
StockCoherus Oncology238.20%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$1.05
Last Closing Price$1.78$1.78$1.78
Upside/Downside---41.01%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26141--6
Feb, 26141--6
Jan, 26131--5
Dec, 25121--4
Nov, 25221--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 24, 2025Ashwani VermaUBS$1.05$1.05--41.01%
Dec 05, 2024Colleen KusyRobert W. Baird$6.00$1.74244.83%237.08%
Nov 14, 2022J.P. Morgan$11.00$7.7941.21%517.98%
Jun 13, 2022Ashwani VermaUBS$7.00$6.1913.09%293.26%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 22, 2026OppenheimerOutperforminitialise
Apr 24, 2025UBSNeutralNeutralhold
Aug 16, 2024UBSBuyNeutraldowngrade
May 30, 2024Cowen & Co.BuyBuyhold
May 10, 2024H.C. WainwrightBuyBuyhold
Mar 28, 2023UBSNeutralBuyupgrade
Jun 13, 2022UBSNeutralinitialise
Apr 26, 2022Zacks Investment ResearchHoldupgrade

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.81$-3.76$-2.53$0.25$1.43---
Avg Forecast$-3.62$-3.62$-1.94$0.35$-0.43$-0.73$-0.75$-0.64
High Forecast$-2.97$-2.46$-1.07$0.36$-0.24$0.09$-0.42$-0.35
Low Forecast$-4.65$-4.36$-2.44$0.35$-0.54$-1.44$-0.95$-0.80
Surprise %5.25%3.87%30.41%-28.57%-432.56%---

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$326.55M$211.04M$257.24M$266.96M$42.17M---
Avg Forecast$335.74M$213.31M$262.80M$256.37M$217.04M$267.61M$240.11M$324.87M
High Forecast$409.35M$246.88M$314.63M$306.93M$278.88M$320.39M$287.46M$388.94M
Low Forecast$289.86M$160.88M$172.65M$168.42M$91.90M$175.81M$157.74M$213.42M
Surprise %-2.74%-1.06%-2.11%4.13%-80.57%---

Net Income Forecast

$-8B $-6B $-4B $-3B $-1B $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-287.10M$-291.75M$-237.89M$28.51M$168.02M---
Avg Forecast$-6.15B$-197.44M$-237.89M$33.26M$-36.83M$-44.81M$-70.94M$-60.26M
High Forecast$-4.92B$-157.95M$-190.31M$33.73M$-22.54M$8.79M$-39.30M$-33.39M
Low Forecast$-7.38B$-236.92M$-285.47M$32.78M$-51.12M$-135.49M$-89.12M$-75.71M
Surprise %-95.33%47.77%--14.28%-556.20%---

CHRS Forecast FAQ

Is Coherus Oncology stock a buy?

Coherus Oncology stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Coherus Oncology is a favorable investment for most analysts.

What is Coherus Oncology's price target?

Coherus Oncology's price target, set by 16 Wall Street analysts, averages $6.02 over the next 12 months. The price target range spans from $1.05 at the low end to $11 at the high end, suggesting a potential 238.20% change from the previous closing price of $1.78.

How does Coherus Oncology stock forecast compare to its benchmarks?

Coherus Oncology's stock forecast shows a 238.20% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Coherus Oncology over the past three months?

  • March 2026: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Coherus Oncology’s EPS forecast?

Coherus Oncology's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.73, marking a -151.05% decrease from the reported $1.43 in 2025. Estimates for the following years are $-0.75 in 2027, and $-0.64 in 2028.

What is Coherus Oncology’s revenue forecast?

Coherus Oncology's average annual revenue forecast for its fiscal year ending in December 2026 is $267.61M, reflecting a 534.57% increase from the reported $42.17M in 2025. The forecast for 2027 is $240.11M, and $324.87M for 2028.

What is Coherus Oncology’s net income forecast?

Coherus Oncology's net income forecast for the fiscal year ending in December 2026 stands at $-44.814M, representing a -126.67% decrease from the reported $168.02M in 2025. Projections indicate $-70.936M in 2027, and $-60.264M in 2028.